May 6, 2026
Popular weight loss drugs like Ozempic do more than help manage diabetes and obesity. They may have benefits for the brain as well. A new analysis found that the medications, known as GLP-1 drugs, appear to lower brain levels of two brain proteins that are a hallmark of Alzheimer’s disease: beta-amyloid and tau.
For the study, researchers at Anglia Ruskin University in the U.K. analyzed data from 32 studies examining the effects of GLP-1 drugs on the brain. Thirty of the studies were conducted in test tube samples of brain tissue or in animals, including mice that had been bred to develop a disease resembling Alzheimer’s in people. Published studies of the effects of these drugs on the brains of people are still limited, though two were included in this review.
Overall, the test tube and animal studies indicated that GLP-1 drugs reduced brain levels of beta-amyloid and tau. Beta amyloid clumps together to form hard plaques in the brain, while tau forms spaghetti-like tangles that choke off healthy brain cells. The two studies in humans found that the drugs had beneficial effects on the brain’s use of glucose and insulin, signs of brain health that may signal a lower risk of Alzheimer’s disease. The findings were published in the journal Molecular and Cellular Neuroscience.
“This new review provides one of the most comprehensive analyses so far of how GLP‑1 drugs interact with the underlying mechanisms of Alzheimer’s,” said Simon Cork, the study’s lead author. “Our study highlights several biological pathways by which GLP‑1 drugs may influence Alzheimer’s, including reducing inflammation, improving insulin signaling in the brain, and altering enzymes involved in the production of beta-amyloid.”
Diabetes is a well-known risk factor for dementia, in part because high blood sugar levels can damage blood vessels throughout the body, including in the brain. Obesity, too, is a known risk factor for Alzheimer’s disease, in part because it is tied to high levels of inflammation throughout the body. Increasingly, researchers recognize the links between cardiovascular health, body-wide inflammation and Alzheimer’s disease.
Still, it’s unknown whether GLP-1s can help prevent cognitive decline or help ward off Alzheimer’s disease. Some studies suggest that the drugs may help to prevent the onset of dementia before symptoms arise but have limited benefits once memory loss and thinking problems become apparent.
“While human studies demonstrating an impact on cognitive decline are still lacking,” Dr. Cork said, “the current evidence points towards these drugs having a preventative effect, rather than in patients with established cognitive impairment.”
GLP-1s include such drugs as semaglutide, which has been used for more than 15 years to regular blood sugar in diabetes and is the active ingredient in the popular weight loss drugs Wegovy and Ozempic. Other, newer GLP-1 drugs include Mounjaro and Zepbound. They have traditionally been given by injection, but newer pill forms are becoming available.
More study is needed before these drugs can be recommended as a preventive measure against Alzheimer’s disease. Whether you are taking weight loss drugs or not, experts stress the importance of regular physical activity and a heart-healthy diet to help maintain brain health.
By ALZinfo.org, The Alzheimer’s Information Site. Reviewed by Eric Schmidt, PhD, of The Fisher Center lab at The Rockefeller University.
Eve Corcoran, Michael Kettlety, Urwa Mogul, et al: “The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review.” Molecular and Cellular Neuroscience, April 20, 2026
